Navigation Links
Alimera Sciences' Iluvien(TM) Phase 3 Studies for DME Pass Final DSMB Review Prior to October Readout
Date:4/8/2009

vitreal injection, a procedure commonly employed by retinal specialists.

Currently, nearly 24 million people, or 8 percent of the population, in the U.S. have diabetes. Over time, all diabetics are at risk of developing some form of diabetic retinopathy, an ophthalmic condition of diabetes. In the U.S., diabetic retinopathy causes approximately 12,000 to 24,000 new cases of blindness each year, making diabetes the leading cause of new cases of blindness in adults aged 20 to 74. Based on published data, Alimera estimates that there are as many as 300,000 new cases of DME each year and 1,000,000 people have DME. There are no ophthalmic drug therapies currently approved by the U.S. Food and Drug Administration for the treatment of DME.

About Alimera Sciences, Inc.

Alimera Sciences is a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals. Presently the company is focused on diseases affecting the back of the eye, or retina. Its most advanced product candidate is Iluvien(TM), which is being developed for the treatment of diabetic macular edema, or DME. DME is a disease of the retina, which affects individuals with diabetes and can lead to severe vision loss and blindness. Under one protocol, enrollment was completed in October 2007 in two Phase 3 pivotal trials for the use of Iluvien in the treatment of DME conducted across the U.S., Canada, Europe and India.

Alimera also has entered into an exclusive worldwide agreement with Emory University to explore oxidative stress management -- specifically the reduction of reactive oxygen species (ROS) -- as a treatment strategy for ophthalmic diseases. Under this agreement, Alimera has acquired options to exclusive, worldwide licenses for two classes of nicotinamide adenine dinucleotide phosphate reduced form (NADPH) oxi
'/>"/>

SOURCE Alimera Sciences, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Alimera Reports Favorable Safety and Efficacy Results From the 12-Month Interim Readout of the Human PK Iluvien(TM) Study
2. Alimera Reports Results From the Six-Month Interim Readout of the Human PK Iluvien(TM) Study
3. DSMB Again Supports Continuation of Alimera Sciences Phase 3 Clinical Trial of Iluvien(TM) for the Treatment of DME
4. Alimera Reports Results From the Three-Month Interim Readout of the Human PK Medidur(TM) FA Study
5. YM BIOSCIENCES ANNOUNCES NIMOTUZUMAB PRESENTATIONS TO BE MADE AT THE 100TH ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH AND EUROPEAN SOCIETY FOR MEDICAL ONCOLOGY
6. Human Genome Sciences Announces Positive Results in Second of Two Phase 3 Trials of Albuferon(R) in Chronic Hepatitis C
7. Sangamo BioSciences Announces Presentations at Two Upcoming Investor Conferences
8. Hana Biosciences Announces New Positive Interim Efficacy Results in Pivotal rALLy Clinical Trial of Marqibo in Acute Lymphoblastic Leukemia
9. Intellect Neurosciences, Inc. Announces Independent Studies on Copper Binding Properties of its Lead Candidate OXIGON(TM)
10. Hana Biosciences Announces Successful Planned Independent Safety Analysis Supports Ability to Complete Pivotal rALLy Clinical Trial of Marqibo, Its Lead Novel Anti-Cancer Compound
11. Human Genome Sciences Announces Fourth-Quarter and Full-Year 2008 Financial Results and Key Developments
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... , Aug. 28, 2015 ... addition of the "Investigation Report on China,s Ranibizumab ... Developed by Novartis, ranibizumab was approved by CFDA to ... Currently, only Lucentis, a product of Novartis, is available ... the first self- developed drug for the treatment of ...
(Date:8/28/2015)... 28, 2015  IP Shakti, LLC, today announced that it ... Logo - http://photos.prnewswire.com/prnh/20150827/261551LOGO ... new corporate identity signifies our transformation into a company focused ... platform for patent claim validity." ... proprietary AIA Shield™ platform, the Company commenced a corporate re-branding ...
(Date:8/28/2015)...  Perrigo Company plc ("Perrigo") (NYSE: PRGO ; ... of leading OTC brands from GSK in an all ... a clear demonstration of Perrigo,s unique ability to maximize ... spanning 36 countries.  Perrigo Chairman, President ... are excited to complete this transaction, which clearly demonstrates ...
Breaking Medicine Technology:Investigation Report on China's Ranibizumab Market, 2012-2019 2IP Shakti, LLC Changes Company Name to Prediqtus, LLC 2Perrigo Completes Acquisition of Leading Portfolio of OTC Brands from GSK 2Perrigo Completes Acquisition of Leading Portfolio of OTC Brands from GSK 3Perrigo Completes Acquisition of Leading Portfolio of OTC Brands from GSK 4
(Date:8/30/2015)... ... , ... Certified Nutrition Businessman Reid Eckert agrees to extend his business relationship ... global sales and communications firm that offers U.S. brands a proven path to world ... Mr. Reid Eckert, as his interpretation of the nutritional needs of the human body ...
(Date:8/29/2015)... ... 30, 2015 , ... On September 30, 2015, the Career and Transfer Center ... accredited Maricopa Community Colleges , will be hosting a Job Expo to provide ... and opportunities. , The Expo has expanded to much more than just a typical ...
(Date:8/29/2015)... , ... August 29, 2015 , ... ... develops, may extend and improve the lives of patients, according to a newly ... Click here to read the full article. , The authors of the ...
(Date:8/29/2015)... ... August 29, 2015 , ... ... chronic obstructive pulmonary disease (including emphysema), or asthma, are at higher risk from ... previous heart attack, heart failure or heart-rhythm problems (arrhythmia or irregular heartbeat) are ...
(Date:8/28/2015)... ... August 28, 2015 , ... Joining a growing number ... recently transitioned management companies to partner with Wound Care Advantage (WCA) to utilize ... center. , Transitioning wound care management providers can be a complex undertaking. ...
Breaking Medicine News(10 mins):Health News:Nutrition Guru Continues Relationship With Renowned Health and Wellness Company 2Health News:Estrella Mountain Community College Expo Offers ‘One-Stop’ for Employers and Students Seeking Internships, Jobs, Careers and Service Learning Opportunities 2Health News:Top Mesothelioma Researchers Highlight Targeted Therapies in New Report, According to Surviving Mesothelioma 2Health News:Heart Fit Clinic Sounds the Alarm on Forest Fire Smoke and Chronic Heart Disease in Calgary Area 2Health News:Decatur County Memorial Hospital Transitions Wound Center Management To Wound Care Advantage and the Luvo Operating System 2Health News:Decatur County Memorial Hospital Transitions Wound Center Management To Wound Care Advantage and the Luvo Operating System 3Health News:Decatur County Memorial Hospital Transitions Wound Center Management To Wound Care Advantage and the Luvo Operating System 4
... on finding the mechanism involved in sleep regulation, the ... to be head by Professor Tarja Porkka-Heiskanen, // Institute ... at finding the mechanisms involved in sleep regulation which ... sleep required for proper functioning of brain and will ...
... Health Association (CMHA) has called for better training for policemen ... The Alberta Police had used a Taser on a man, ... opinion that this could have been avoided if specialized training ... ,The victim was a well-dressed man who was apparently going ...
... feces as food for fish growth as increased the widespread fear ... // with the feces to pond farms which may infect wild ... flu virus. Researchers feel that the bird flu outbreak in china ... as feed for fishes in the river Qinghai, which would have ...
... University of Chicago are developing drugs which help in ... by developing mechanisms which helps// in maintaining the lung ... avoid inflammatory cells produced by the cytokines (immune cells) ... increased inflammation and leakage in blood vessels leading to ...
... Lupus erythematosus (lupus) is a disease in which the ... of the skin, joints and internal organs.// A study ... can take oral contraceptives safely without any complications like ... activity, that characterize the disease. ,The study ...
... has collected $2.3 million to be donated to a ... radio programs // . ,The money will be ... Brampton Hospital at Bovaird Drive and Bramalea Road, which ... event, Better Health Radiothon, was organized from Nov 15 ...
Cached Medicine News:
... Now there is a more efficient ... first fully portable battery operated patient ... and surgical teams with a compact ... throughout the entire surgical process. Its ...
... CSZ safely provides effective air warming therapy ... patented design of our WarmAir® FilteredFlo® blankets, ... which supplies gently moving, clean air that ... contaminants to your patient or staff. All ...
Since 1964, in its plants of Sesto Fiorentino, Sbisà produces a wide and qualified range of instruments for ophthalmology and optometry....
Inquire...
Medicine Products: